Reneuron Share Discussion Threads

[supernumerary] 01/5/2018 22:20

In my experience it's either a hidden clinical disaster, or a fund wants out regardless of price. The first is a good potential short, the second an equally good potential long.

But which is it? Or of course something else entirely...

[audigger] 01/5/2018 21:52

Only just caught up with today's market moves. Can't believe this has tanked so badly. Post consolidation drop was to be expected but this now appears to be written off in terms of clinical potential. I've taken some big hits on life science start-ups and this looks to be another

[supernumerary] 01/5/2018 20:14

Is somebody dumping these? science looks OK. They only list 4 major shareholders - Woodford, Wales Life Sciences, Invesco and Aviva - has somebody decided to go awol? Biggish volume today, TR-1 to come maybe?

I knew that 100:1 would be painful for holders...

[volsung] 01/5/2018 19:36

Evening algernon. Been better.

[algernon2] 01/5/2018 18:31

Evening Volsung, Bigspuds, not too good at the moment is it?

[volsung] 01/5/2018 15:18

Mind you I have bought most of it at some point

[bigspuds] 17/4/2018 08:47

Not that we're any better fixed lol

[bigspuds] 17/4/2018 08:46

IMM.......not good, hope no-one here followed that pump and dump

[billiondollarbrain] 16/4/2018 16:16

Immupharma (IMM) Phase III Lupuzor results expected this week.

Possible $ multi-billion blockbuster could lead to a massive re-rating of the share price.



This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Tempted? If so, it’s vital to consider the flip side of this investment.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

No investment is devoid of risk but only you can decide whether this is one worth taking.

[rocket fuel] 16/4/2018 13:17

expect another 50% dilution here if you're lucky, that's if they can get away with it again after raising more than £200m since second bite of the ipo cherry. if not, it will be time to put this dog down and delist.

[bantam175] 16/4/2018 13:11

.7p in old money. wtf?

[billiondollarbrain] 06/4/2018 11:34

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"The pharmaceuticals space in 2018 is jam-packed with potentially game-changing clinical trial results.

Drug developer ImmuPharma (IMM:AIM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."


This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Tempted? If so, it’s vital to consider the flip side of this investment.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

No investment is devoid of risk but only you can decide whether this is one worth taking.

[audigger] 03/4/2018 14:55

Grimsville; shafting continues.

[rotors] 30/3/2018 11:29

"Rotors 19 Dec '17 - 20:51 - 5386 of 5466

1. Boston office = NASDAQ quote?"
----------------------------------

If there is no NASDAQ quote (and US interest) forthcoming I fear we are in for a torrid time.

Progress is slow, continued good news posts are met with a falling share price which is now below the cash value.

I assume Mr Woodford was consulted on the share consolidation which seems to have backfired.

There will also be sales up to the end of the tax year for those looking to offset gains elsewhere.

A grim picture.
(EDIT ..... for shareholders and those looking for medical progress)

[seans66] 30/3/2018 07:29

I am out & taken a big loss. After more than 2 years of continual share price falls & no likelihood of a recovery in the next 12 months, I decided what was left of my investment could be more productive elsewhere. Good luck to LTHs I hope it eventually comes good.

[algernon2] 29/3/2018 17:01

Yes depressing watching isn't it.

[stewart_25] 29/3/2018 13:33

no value left here. lots of money lost....

[dmhzx] 28/3/2018 22:35

And to think of all the money they wasted on share consolidation. Soon be back to a few pence again

[waterloo01] 26/3/2018 16:56

Nothing much happening in 2018 and not much reason to invest IMO.

[dickbush] 26/3/2018 16:31

News of a more expensive tomorrow.

[waterloo01] 20/3/2018 12:26

No it isn't as this and many of the next wave of studies use patients own stem cells, which is an increasing trend and one reason this is under £1.00

[stewart_25] 20/3/2018 12:23

great news - but is rene directly involved with this particular news article - no reference if so...